Open AccessMicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer
Author(s) -
Marion Gayral,
Sebastien M. Joruiz,
Naı̈ma Hanoun,
Alix VignolleVidoni,
Hubert Lulka,
Yannick Delpu,
Aline Meulle,
Marlène Dufresne,
Marine Humeau,
M. Chalret du Rieu,
Barbara Bournet,
Janick Sèlves,
Rosine Guimbaud,
Nicolas Carrère,
Louis Buscail,
Jérôme Torrisani,
Pierre Cordelier
Publication year - 2014
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v20.i32.11199
Subject(s) - pancreatic cancer , medicine , disease , microrna , cancer , overall survival , oncology , bioinformatics , pancreatic ductal adenocarcinoma , biology , biochemistry , gene
Despite tremendous efforts from scientists and clinicians worldwide, pancreatic adenocarcinoma (PDAC) remains a deadly disease due to the lack of early diagnostic tools and reliable therapeutic approaches. Consequently, a majority of patients (80%) display an advanced disease that results in a low resection rate leading to an overall median survival of less than 6 months. Accordingly, robust markers for the early diagnosis and prognosis of pancreatic cancer, or markers indicative of survival and/or metastatic disease are desperately needed to help alleviate the dismal prognosis of this cancer. In addition, the discovery of new therapeutic targets is mandatory to design effective treatments. In this review, we will highlight the translational studies demonstrating that microRNAs may soon translate into clinical applications as long-awaited screening tools and therapeutic targets for PDAC.